Susquehanna Fundamental Investments’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Susquehanna Fundamental Investments’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,581	Closed	-$205K	–	1938
2021 Q2	$205K	Sell	1,581 -49	-3%	-$6.78K	﹤0.01%	1477
2021 Q1	$268K	Sell	1,630 -11	-0.7%	-$2.12K	﹤0.01%	1325
2020 Q4	$384K	Buy	1,641 +355	+28%	+$49.4K	0.01%	1189
2020 Q3	$133K	Buy	+1,286	New	+$68.9K	﹤0.01%	1251

Other funds holding TCON

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Susquehanna Fundamental Investments's TCON Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q3 2021, closing a stake of 1,581 shares — an estimated $205K sold.

Susquehanna Fundamental Investments first reported a position in TCON in Q3 2020 and held it in 4 quarters. The position peaked at $384K in Q4 2020. 44 funds tracked by Wall St. Rank hold TCON as of Q3 2021.

Susquehanna Fundamental Investments reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Susquehanna Fundamental Investments sold 1,581 TRACON Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $205K.
Susquehanna Fundamental Investments first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 4 quarters.
Susquehanna Fundamental Investments's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $384K in Q4 2020.
44 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.